Skip to main content

Table 2 Disease progression and relapses for the intention-to-treat population for whom relapse/EDSS data were available (n=436)

From: Clinical characteristics of middle-aged and older patients with MS treated with interferon beta-1b: post-hoc analysis of a 2-year, prospective, international, observational study

Parameter

Number (%) patients

Aged 41–50 years (n=301)

Aged >50 years (n=135)

EDSS score:

  improvement (≤–1)

33 (11.0%)

12 (8.9%)

  stable (no change)

219 (72.8%)

90 (66.7%)

  progression (≥+1)

49 (16.3%)

33 (24.4%)

Relapse free throughout the study

272 (90.4%)

127 (94.1%)

Disease-progression freea

252 (83.7%)

102 (75.6%)

Relapse free and disease-progression free

228 (75.7%)

96 (71.1%)

  1. aDisease-progression free defined as EDSS that were stable (change of up to ±1) or improved (at least 1-point decrease) at last patient visit.
  2. EDSS expanded disability status scores.